Therapeutic vaccines for breast cancer: Has the time finally come?

Chiara Corti, Pier P.M.B. Giachetti, Alexander M.M. Eggermont, Suzette Delaloge, Giuseppe Curigliano

Onderzoeksoutput: Bijdrage aan tijdschriftArtikel recenserenpeer review

46 Citaten (Scopus)


The ability to exploit the immune system as a weapon against cancer has revolutionised the treatment of cancer patients, especially through immune checkpoint inhibitors (ICIs). However, ICIs demonstrated a modest benefit in treating breast cancer (BC), with the exception of certain subsets of triple-negative BCs. An immune-suppressive tumour microenvironment (TME), typically present in BC, is an important factor in the poor response to immunotherapy. After almost two decades of poor clinical trial results, cancer vaccines (CVs), an active immunotherapy, have come back in the spotlight because of some technological advancements, ultimately boosted by coronavirus disease 2019 pandemic. In particular, neoantigens are emerging as the preferred targets for CVs, with gene-based and viral vector–based platforms in development. Moreover, lipid nanoparticles proved to be immunogenic and efficient delivery vehicles. Past clinical trials investigating CVs focused especially on the metastatic disease, where the TME is more likely compromised by inhibitory mechanisms. In this sense, favouring the use of CVs as monotherapy in premalignant or in the adjuvant setting and establishing combination treatments (i.e. CV plus ICI) in late-stage disease are promising strategies. This review provides a full overview of the past and current breast cancer vaccine landscape.

Originele taal-2Engels
Pagina's (van-tot)150-174
Aantal pagina's25
TijdschriftEuropean Journal of Cancer
StatusGepubliceerd - jan. 2022


Duik in de onderzoeksthema's van 'Therapeutic vaccines for breast cancer: Has the time finally come?'. Samen vormen ze een unieke vingerafdruk.

Citeer dit